1. At a Glance
In the great Indian pharma bazaar, Akums Drugs & Pharmaceuticals Ltd (BSE: 544222 | NSE: AKUMS) is that one CDMO giant quietly filling your prescriptions while the brand name takes all the credit. Established in 2004, this ₹6,640 crore market cap company manufactures more pills, syrups, and ampoules than most doctors can pronounce in a lifetime. In FY24, Akums grabbed a 30.2% market share in India’s CDMO segment, manufacturing for 26 of the top 30 pharma players, including Cipla, Dr. Reddy’s, and Dabur.
Yet, Q2FY26 wasn’t a perfect prescription — sales stood at ₹1,018 crore, down 1.51% QoQ, and PAT fell 34.8% to ₹40.8 crore. But behind the quarterly sniffle lies a global ambition — new patents, partnerships, and even a ₹200 crore manufacturing investment in Zambia!
At ₹422 a share, the stock trades at a P/E of 21.6, ROE 17.2%, and ROCE 16.2%. With 12 factories, 49.23 billion units of annual capacity, and a current ratio of 3.95, Akums looks like the disciplined pharmacy student everyone copies from.
And as the Bhagavad Gita reminds us:
“Karmanye vadhikaraste, ma phaleshu kadachana” — do your work, not for the fruit. But Akums’ fruit happens to be ₹308 crore in profit. 🍇
2. Introduction – The Pill Pusher with a Plan
Every Indian has likely swallowed something made by Akums, but few have heard of it. That’s the beauty of being a contract development and manufacturing organization (CDMO) — the invisible force behind your branded drugs. While Sun Pharma and Dr. Reddy’s hog the limelight, Akums quietly churns out the formulations, bottles, and blisters that make them shine.
The company is basically the “TCS of Tablets” — doing the hard work for other people’s logos. With a product portfolio spanning 4,146 formulations across 60 dosage forms, Akums doesn’t make blockbuster drugs; it makes blockbusters possible.
In the last few years, it’s been on an expansion spree — from buying Akums Lifesciences (ex-Parabolic Drugs) for API manufacturing, to setting up a new injectable facility (FY25), and signing a €200 million European CDMO contract.
Despite a rough patch in recent quarters, Akums has maintained a steady 49% profit CAGR over five years, showing the resilience of a pharmacist surviving GST audits, DCGI inspectors, and tax searches (yes, that happened in Jan 2025 — classic “routine scrutiny”).
So while the market yawns at its modest topline growth, Akums seems to be playing the long game — one where volume, compliance, and quiet dominance beat hype.
3. Business Model – WTF Do They Even Do?
Think of Akums as the Amazon Fulfillment Center for Pharma. Pharma brands ideate, Akums manufactures.
Here’s how the medicine magic works:
- CDMO Segment (78.2% of revenue): Big pharma outsources the headache — Akums handles formulation, testing, packaging, and regulatory approvals. Basically, they rent their factories, brains, and licenses.
- Branded & Generic Segment (16.8%): Here, Akums acts like a junior doctor trying his own clinic — selling branded drugs under in-house labels.
- API Manufacturing (5%): After acquiring Parabolic Drugs’ assets, Akums started making its own active ingredients — a nice backward integration story.
Their 12 manufacturing facilities pump out tablets, capsules, injectables, syrups, and even gummies (yes, multivitamin candies for millennials who refuse pills). With 49.23 billion units annual capacity, Akums is to Indian pharma what Parle is to biscuits.
Globally, it exports to 65 countries
